Upregulation of cytoplasmic gelsolin, an amyloid-β-binding protein, under oxidative stress conditions: Involvement of protein kinase C

Journal of Alzheimer's Disease

Volumn 19, Issue 3, 2010, Pages 829-838

  Ji, Lina ^a   Chauhan, Abha ^a   Chauhan, Ved ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Gelsolin; Mitogen activated protein kinases; Oxidative stress; Protein kinase C

Indexed keywords

AMYLOID BETA PROTEIN; CALPHOSTIN C; CYCLOHEXIMIDE; CYTOPLASMIC GELSOLIN; GELSOLIN; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; STAUROSPORINE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION; WESTERN BLOTTING;

EID: 77149151225     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1281     Document Type: Article

References (59)

1. Yin HL, Kwiatkowski DJ, Mole JE, Cole FS (1984) Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J Biol Chem 259, 5271-5276.
2. Wen D, Corina K, Chow EP, Miller S, Janmey PA, Pepinsky RB (1996) The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35, 9700-9709.
3. Sun HQ, Yamamoto M, Mejillano M, Yin HL (1999) Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 274, 33179-33182.
4. Witke W, Sharpe AH, Hartwig JH, Azuma T, Stossel TP, Kwiatkowski DJ (1995) Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 81, 41-51.
5. Endres M, Fink K, Zhu J, Stagliano NE, Bondada V, Geddes JW, Azuma T, Mattson MP, Kwiatkowski DJ, Moskowitz MA (1999) Neuroprotective effects of gelsolin during murine stroke. J Clin Invest 103, 347-354.
6. Yildirim F, Gertz K, Kronenberg G, Harms C, Fink KB, Meisel A, Endres M (2008) Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 210, 531-542.
7. Leifeld L, Fink K, Debska G, Fielenbach M, Schmitz V, Sauerbruch T, Spengler U (2006) Anti-apoptotic function of gelsolin in fas antibody-induced liver failure in vivo. Am J Pathol 168, 778-785.
8. Janmey PA (1994) Phosphoinositides and calcium as regulators of cellular actin assembly and disassembly. Annu Rev Physiol 56, 169-191.
9. Singh SS, Chauhan A, Murakami N, Chauhan VP (1996) Profilin and gelsolin stimulate phosphatidylinositol 3-kinase activity. Biochemistry 35, 16544-16549. (Pubitemid 27020496)
10. Asch HL, Head K, Dong Y, Natoli F,Winston JS, Connolly JL, Asch BB (1996) Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 56, 4841-4845.
11. Prasad SC, Thraves PJ, Dritschilo A, Kuettel MR (1997) Protein expression changes associated with radiation-induced neoplastic progression of human prostate epithelial cells. Electrophoresis 18, 629-637.
12. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, Katoh H, Kawakami Y, Kuzumaki N (1998) Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58, 322-327.
13. Maury CP, Sletten K, Totty N, Kangas H, Liljestrom M(1997) Identification of the circulating amyloid precursor and other gelsolin metabolites in patients with G654A mutation in the gelsolin gene (Finnish familial amyloidosis): pathogenetic and diagnostic implications. Lab Invest 77, 299-304.
14. GlennerGG(1983) Alzheimer's disease. The commonest form of amyloidosis. Arch Pathol Lab Med 107, 281-282.
15. Tanaka J, Sobue K (1994) Localization and characterization of gelsolin in nervous tissues: gelsolin is specifically enriched in myelin-forming cells. J Neurosci 14, 1038-1052.
16. Chauhan VP, Ray I, Chauhan A,Wisniewski HM(1999) Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochem Biophys Res Commun 258, 241-246.
17. Hirko AC, Meyer EM, King MA, Hughes JA(2007) Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol Ther 15, 1623-1629.
18. Ji L, Chauhan A, Chauhan V (2008) Cytoplasmic gelsolin in pheochromocytoma-12 cells forms a complex with amyloid beta-protein. Neuroreport 19, 463-466.
19. Antequera D, Vargas T, Ugalde C, Spuch C, Molina JA, Ferrer I, Bermejo-Pareja F, Carro E (2009) Cytoplasmic gelsolin increases mitochondrial activity and reduces Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Dis 36, 42-50.
20. Ray I, Chauhan A, Wegiel J, Chauhan VP (2000) Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res 853, 344-351.
21. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23, 29-33.
22. Chauhan V, Chauhan A (2006) Oxidative stress in Alzheimer's disease. Pathophysiology 13, 195-208.
23. Obrig TG, Culp WJ, McKeehan WL, Hardesty B (1971) The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem 246, 174-181.
24. Toledo LM, Lydon NB (1997) Structures of staurosporine bound to CDK2 and cAPK-new tools for structure-based design of protein kinase inhibitors. Structure 5, 1551-1556.
25. Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81, 807-869.
26. Ohori M, Kinoshita T, Okubo M, Sato K, Yamazaki A, Arakawa H, Nishimura S, Inamura N, Nakajima H, Neya M, Miyake H, Fujii T (2005) Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 336, 357-363.
27. Deng R, Li W, Guan Z, Zhou JM, Wang Y, Mei YP, Li MT, Feng GK, Huang W, Liu ZC, Han Y, Zeng YX, Zhu XF (2006) Acetylcholinesterase expression mediated by c-Jun- NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene 25, 7070-7077.
28. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL (1988) Muscle is the major source of plasma gelsolin. J Biol Chem 263, 8239-8243.
29. Kwiatkowski DJ, Mehl R, Yin HL (1988) Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J Cell Biol 106, 375-384.
30. Vegesna RV, Wu HL, Mong S, Crooke ST (1988) Staurosporine inhibits protein kinase C and prevents phorbol estermediated leukotriene D4 receptor desensitization in RBL-1 cells. Mol Pharmacol 33, 537-542.
31. Lin D, Takemoto DJ (2005) Oxidative activation of protein kinase Cgamma through the C1 domain. Effects on gap junctions. J Biol Chem 280, 13682-13693.
32. Azuma T, Koths K, Flanagan L, Kwiatkowski D (2000) Gelsolin in complex with phosphatidylinositol 4,5-bisphosphate inhibits caspase-3 and -9 to retard apoptotic progression. J Biol Chem 275, 3761-3766.
33. Koya RC, Fujita H, Shimizu S, Ohtsu M, Takimoto M, Tsujimoto Y, Kuzumaki N (2000) Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem 275, 15343-15349.
34. Kusano H, Shimizu S, Koya RC, Fujita H, Kamada S, Kuzumaki N, Tsujimoto Y (2000) Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene 19, 4807-4814.
35. Harms C, Bosel J, Lautenschlager M, Harms U, Braun JS, Hortnagl H, Dirnagl U, Kwiatkowski DJ, Fink K, Endres M (2004) Neuronal gelsolin prevents apoptosis by enhancing actin depolymerization. Mol Cell Neurosci 25, 69-82.
36. Yermen B, Tomas A, Halban PA (2007) Pro-survival role of gelsolin in mouse beta-cells. Diabetes 56, 80-87.
37. Qiao H, Koya RC, Nakagawa K, Tanaka H, Fujita H, Takimoto M, Kuzumaki N (2005) Inhibition of Alzheimer's amyloidbeta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging 26, 849-855.
38. Ohtsu M, Sakai N, Fujita H, Kashiwagi M, Gasa S, Shimizu S, Eguchi Y, Tsujimoto Y, Sakiyama Y, Kobayashi K, Kuzumaki N (1997) Inhibition of apoptosis by the actin-regulatory protein gelsolin. EMBO J 16, 4650-4656.
39. Meisel A, Harms C, Yildirim F, Bosel J, Kronenberg G, Harms U, Fink KB, Endres M (2006) Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J Neurochem 98, 1019-1031.
40. McDonagh B, Sheehan D (2007) Effect of oxidative stress on protein thiols in the blue mussel Mytilus edulis: proteomic identification of target proteins. Proteomics 7, 3395-3403.
41. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW (2001) Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res 898, 350-357.
42. LeBlanc A, Liu H, Goodyer C, Bergeron C,HammondJ (1999) Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem 274, 23426-23436.
43. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E (2002) Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 11, 341-354. (Pubitemid 36135697)
44. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, VitekMP, LaFerla FM, RohnTT, CotmanCW(2004) Caspasecleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114, 121-130.
45. Mouser PE, Head E, Ha KH, Rohn TT (2006) Caspasemediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol 168, 936-946.
46. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, CotmanCW, Cribbs DH (2001) Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 158, 189-198.
47. Petersen RC, Smith GE, Ivnik RJ, Kokmen E, Tangalos EG (1994) Memory function in very early Alzheimer's disease. Neurology 44, 867-872.
48. Bank B, DeWeer A, Kuzirian AM, Rasmussen H, Alkon DL (1988) Classical conditioning induces long-term translocation of protein kinase C in rabbit hippocampal CA1 cells. Proc Natl Acad Sci U S A 85, 1988-1992.
49. Olds JL, Alkon DL (1993) Protein kinase C: a nexus in the biochemical events that underlie associative learning. Acta Neurobiol Exp (Wars) 53, 197-207.
50. Pascale A, Govoni S, Battaini F (1998) Age-related alteration of PKC, a key enzyme in memory processes: physiological and pathological examples. Mol Neurobiol 16, 49-62.
51. Cole G, Dobkins KR, Hansen LA, Terry RD, Saitoh T (1988) Decreased levels of protein kinase C in Alzheimer brain. Brain Res 452, 165-174.
52. Govoni S, Bergamaschi S, Racchi M, Battaini F, Binetti G, Bianchetti A, Trabucchi M (1993) Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients. Neurology 43, 2581-2586.
53. Wang HY, Pisano MR, Friedman E (1994) Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. Neurobiol Aging 15, 293-298.
54. Kurumatani T, Fastbom J, Bonkale WL, Bogdanovic N, Winblad B, Ohm TG, Cowburn RF (1998) Loss of inositol 1,4,5- trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Res 796, 209-221.
55. Desdouits F, Buxbaum JD, Desdouits-Magnen J, Nairn AC, Greengard P (1996) Amyloid alpha peptide formation in cellfree preparations. Regulation by protein kinase C, calmodulin, and calcineurin. J Biol Chem 271, 24670-24674.
56. Favit A, Grimaldi M, Nelson TJ, Alkon DL (1998) Alzheimer's-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts. Proc Natl Acad Sci U S A 95, 5562-5567.
57. Pakaski M, Balaspiri L, Checler F, Kasa P (2002) Human amyloid-beta causes changes in the levels of endothelial pro tein kinase C and its alpha isoform in vitro. Neurochem Int 41, 409-414.
58. Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL (2004) Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A 101, 11141-11146.
59. Kozikowski AP, Chen Y, Subhasish T, Lewin NE, Blumberg PM, Zhong Z, D'Annibale MA, Wang WL, Shen Y, Langley B (2009) Searching for disease modifiers-PKC activation and HDAC inhibition-a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. Chem Med Chem 4, 1095-1105.